Xylem said revenue for Q3 2024 rose to $2,104 million, up $28 million (1.3%), and revenue for the 9 months increased to $6,306 million, up $1,060 million (20.2%). Acquisitions, net of divestitures, contributed $782 million of the 9-month increase.

10-QQuarterly reportFiled Oct 31, 2024Period of report Sep 30, 2024Summary published (UTC) Oct 23, 2026

Key points

AI summary

Xylem said revenue for Q3 2024 rose to $2,104 million, up $28 million (1.3%), and revenue for the 9 months increased to $6,306 million, up $1,060 million (20.2%). Acquisitions, net of divestitures, contributed $782 million of the 9-month increase.
The company said operating income for Q3 2024 was $280 million (operating margin of 13.3%), up $89 million from $191 million (9.2%) in the prior-year period. Adjusted operating income was $350 million (adjusted operating margin of 16.6%).
Xylem said operating cash flow for the 9 months of 2024 was $688 million, exceeding $382 million in the prior-year period. It also said its available liquidity, including cash of $989 million and $1 billion of available credit facilities, was approximately $2 billion.
Xylem said it updated its full-year 2024 revenue growth outlook to 15% and its organic revenue growth outlook to approximately 5%. The company said the outlook is based on current visibility and market conditions and is subject to several risks.

Key figures

Quarter ended September 30, 2024

Revenue: $2.1B
Operating income: $280M
Net income: $217M
EPS: $0.89
Gross profit: $784M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Revenue Up Q3 2024 and 9-Month Revenue Growth

Xylem said revenue for Q3 2024 rose to $2,104 million, up $28 million (1.3%), and revenue for the 9 months increased to $6,306 million, up $1,060 million (20.2%). Acquisitions, net of divestitures, contributed $782 million of the 9-month increase.

Source · Based on the MD&A text of the filing

Q3 Operating Income and Adjusted Operating Income

The company said operating income for Q3 2024 was $280 million (operating margin of 13.3%), up $89 million from $191 million (9.2%) in the prior-year period. Adjusted operating income was $350 million (adjusted operating margin of 16.6%).

Source · Based on the MD&A text of the filing

9-Month Operating Cash Flow and Available Liquidity

Xylem said operating cash flow for the 9 months of 2024 was $688 million, exceeding $382 million in the prior-year period. It also said its available liquidity, including cash of $989 million and $1 billion of available credit facilities, was approximately $2 billion.

Source · Based on the MD&A text of the filing

Full-Year Revenue Growth Outlook Updated

Xylem said it updated its full-year 2024 revenue growth outlook to 15% and its organic revenue growth outlook to approximately 5%. The company said the outlook is based on current visibility and market conditions and is subject to several risks.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗